Intellia Therapeutics, Inc. $NTLA Stake Lifted by Cwm LLC

Cwm LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 22.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,331 shares of the company’s stock after buying an additional 3,419 shares during the period. Cwm LLC’s holdings in Intellia Therapeutics were worth $172,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of NTLA. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Intellia Therapeutics by 56.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock worth $33,000 after acquiring an additional 1,655 shares during the period. Harbour Investments Inc. grew its position in Intellia Therapeutics by 76.7% in the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock worth $37,000 after purchasing an additional 2,264 shares during the last quarter. Quantbot Technologies LP increased its stake in shares of Intellia Therapeutics by 846.4% in the first quarter. Quantbot Technologies LP now owns 6,663 shares of the company’s stock valued at $47,000 after purchasing an additional 5,959 shares during the period. 49 Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics in the first quarter valued at approximately $74,000. Finally, Cyndeo Wealth Partners LLC bought a new stake in shares of Intellia Therapeutics during the second quarter valued at approximately $101,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 6.0%

Shares of Intellia Therapeutics stock opened at $13.12 on Thursday. The business has a fifty day simple moving average of $17.03 and a 200-day simple moving average of $12.27. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -2.80 and a beta of 2.37.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The firm had revenue of $14.25 million for the quarter, compared to analysts’ expectations of $12.26 million. During the same period in the previous year, the business earned ($1.52) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 104.3% compared to the same quarter last year. Analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTLA has been the subject of a number of recent analyst reports. Wedbush reissued a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 6th. Guggenheim cut shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday. Finally, Sanford C. Bernstein set a $14.50 price objective on shares of Intellia Therapeutics in a report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $24.95.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares in the company, valued at approximately $960,523.08. The trade was a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William J. Chase purchased 100,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was bought at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the acquisition, the director directly owned 134,693 shares of the company’s stock, valued at $1,350,970.79. This represents a 288.24% increase in their position. The disclosure for this purchase is available in the SEC filing. 3.10% of the stock is owned by insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.